Skip to main content

Advertisement

SpringerLink
Log in

Sebaceous Carcinoma: A Review of the Scientific Literature

  • Skin Cancer (SZ Aasi, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Sebaceous carcinoma is a rare and potentially aggressive cutaneous malignancy. Commonly reported in the periocular area and the head and neck region, sebaceous carcinoma can arise from any sebaceous gland in the skin. The clinical presentation may be nonspecific, and a biopsy is important to establish a diagnosis and to differentiate from mimickers including benign sebaceous neoplasms, other adnexal tumors, and basal cell carcinoma. A diagnosis of Muir Torre syndrome should be considered in patients presenting with a sebaceous neoplasm. Early treatment is important given the potential of sebaceous carcinoma to spread to the regional lymph nodes and beyond. Sentinel lymph node biopsy and imaging to complete tumor staging may be indicated for larger or more aggressive tumors. Surgery, including Mohs micrographic surgery, remains the primary treatment modality for sebaceous carcinoma. Mohs micrographic surgery has the advantage of complete margin evaluation and low recurrence rates. Advanced cases may be treated with orbital exenteration, radiation therapy, chemotherapy, or combination therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Straatsma BR. Meibomian gland tumors. AMA Arch Ophthalmol. 1956;56(1):71–93.

    Article  CAS  PubMed  Google Scholar 

  2. Urban FH, Winkelmann RK. Sebaceous malignancy. Arch Dermatol. 1961;84:63–72.

    Article  CAS  PubMed  Google Scholar 

  3. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65. doi:10.1002/cncr.23952.

    Article  PubMed  Google Scholar 

  4. Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008;113(12):3372–81. doi:10.1002/cncr.23963.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kuzel P, Metelitsa AI, Dover DC, Salopek TG. Epidemiology of sebaceous carcinoma in Alberta, Canada, from 1988 to 2007. J Cutan Med Surg. 2012;16(6):417–23.

    Article  PubMed  Google Scholar 

  6. •• Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75(6):1210–5. doi:10.1016/j.jaad.2016.07.046. Tumor registry study evaluating incidence and survival based on 2200 cases in the SEER database

    Article  PubMed  Google Scholar 

  7. Bailet JW, Zimmerman MC, Arnstein DP, Wollman JS, Mickel RA. Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol-Head Neck Surg. 1992;118(11):1245–9.

    Article  CAS  PubMed  Google Scholar 

  8. Ni C, Searl SS, Kuo PK, Chu FR, Chong CS, Albert DM. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin. 1982;22(1):23–61.

    Article  CAS  PubMed  Google Scholar 

  9. Omura NE, Collison DW, Perry AE, Myers LM. Sebaceous carcinoma in children. J Am Acad Dermatol. 2002;47(6):950–3. doi:10.1067/mjd.2002.114615.

    Article  PubMed  Google Scholar 

  10. Mebazaa A, Boussofara L, Trabelsi A, Denguezli M, Sriha B, Belajouza C, et al. Undifferentiated sebaceous carcinoma: an unusual childhood cancer. Pediatr Dermatol. 2007;24(5):501–4. doi:10.1111/j.1525-1470.2007.00503.x.

    Article  PubMed  Google Scholar 

  11. Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113–22.

    Article  CAS  PubMed  Google Scholar 

  12. Best M, De Chabon A, Park J, Galin MA. Sebaceous carcinoma of glands of Zeis. NY State J Med. 1970;70(3):433–5.

    CAS  Google Scholar 

  13. Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol. 1989;33(6):477–90.

    Article  CAS  PubMed  Google Scholar 

  14. Wolfe JT 3rd, Yeatts RP, Wick MR, Campbell RJ, Waller RR. Sebaceous carcinoma of the eyelid: errors in clinical and pathologic diagnosis. Am J Surg Pathol. 1984;8(8):597–606.

    Article  PubMed  Google Scholar 

  15. Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2002;28(7):623–31.

    Google Scholar 

  16. Bassetto F, Baraziol R, Sottosanti MV, Scarpa C, Montesco M. Biological behavior of the sebaceous carcinoma of the head. Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2004;30(3):472–6.

    Google Scholar 

  17. Sawyer AR, McGoldrick RB, Mackey S, Powell B, Pohl M. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy? Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2009;35(4):704–8.

    Article  CAS  Google Scholar 

  18. Maniglia AJ. Meibomian gland adenocarcinoma of the eyelid with neck metastasis. Laryngoscope. 1978;88(9 Pt 1):1421–6.

    Article  CAS  PubMed  Google Scholar 

  19. Boniuk M, Zimmerman LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans - Am Acad Ophthalmol Otolaryngol. 1968;72(4):619–42.

    CAS  PubMed  Google Scholar 

  20. Berlin AL, Amin SP, Goldberg DJ. Extraocular sebaceous carcinoma treated with Mohs micrographic surgery: report of a case and review of literature. Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2008;34(2):254–7. doi:10.1111/j.1524-4725.2007.34051.x.

    Article  CAS  Google Scholar 

  21. Nelson BR, Hamlet KR, Gillard M, Railan D, Johnson TM. Sebaceous carcinoma. J Am Acad Dermatol. 1995;33(1):1–15. quiz 6-8

    Article  CAS  PubMed  Google Scholar 

  22. Ghosh SK, Bandyopadhyay D, Gupta S, Chatterjee G, Ghosh A. Rapidly growing extraocular sebaceous carcinoma occurring during pregnancy: a case report. Dermatol Online J. 2008;14(8):8.

    PubMed  Google Scholar 

  23. Bhat IP, Madhukara J, Elizabeth J, Kini U, Anuradha A. Multifocal extra-ocular sebaceous carcinoma. Indian J Dermatol Venereol Leprol. 2011;77(3):403. doi:10.4103/0378-6323.79743.

    Article  PubMed  Google Scholar 

  24. Zurcher M, Hintschich CR, Garner A, Bunce C, Collin JR. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol. 1998;82(9):1049–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Khan JA, Doane JF, Grove AS Jr. Sebaceous and meibomian carcinomas of the eyelid recognition, diagnosis, and management. Ophthal Plast Reconstr Surg. 1991;7(1):61–6.

    Article  CAS  PubMed  Google Scholar 

  26. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr. Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol. 2005;32(7):496–501. doi:10.1111/j.0303-6987.2005.00371.x.

    Article  PubMed  Google Scholar 

  27. Escalonilla P, Grilli R, Canamero M, Soriano ML, Farina MC, Manzarbeitia F, et al. Sebaceous carcinoma of the vulva. Am J Dermatopathol. 1999;21(5):468–72.

    Article  CAS  PubMed  Google Scholar 

  28. Leibovitch I, Selva D, Huilgol S, Davis G, Dodd T, James CL. Intraepithelial sebaceous carcinoma of the eyelid misdiagnosed as Bowen’s disease. J Cutan Pathol. 2006;33(4):303–8. doi:10.1111/j.0303-6987.2006.00423.x.

    Article  PubMed  Google Scholar 

  29. Doxanas MT, Green WR. Sebaceous gland carcinoma: review of 40 cases. Arch Ophthalmol (Chicago, Ill : 1960). 1984;102(2):245–9.

    Article  CAS  Google Scholar 

  30. •• Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012;34(12):1765–8. doi:10.1002/hed.22009. Tumor registry study reporting incidence of nodal disease in sebaceous carcinoma and its impact on survival based on 1836 cases in the SEER database

    Article  PubMed  Google Scholar 

  31. Cabral ES, Auerbach A, Killian JK, Barrett TL, Cassarino DS. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am J Dermatopathol. 2006;28(6):465–71. doi:10.1097/01.dad.0000245200.65600.a4.

    Article  PubMed  Google Scholar 

  32. Na HY, Choe JY, Shin SA, Choung HK, Oh S, Chung JH, et al. Proposal of a provisional classification of sebaceous carcinoma based on hormone receptor expression and HER2 status. Am J Surg Pathol. 2016;40(12):1622–30. doi:10.1097/pas.0000000000000728.

    Article  PubMed  Google Scholar 

  33. Stagner AM, Afrogheh AH, Jakobiec FA, Iacob CE, Grossniklaus HE, Deshpande V, et al. p16 expression is not a surrogate marker for high-risk human papillomavirus infection in periocular sebaceous carcinoma. Am J Ophthalmol. 2016;170:168–75. doi:10.1016/j.ajo.2016.07.012.

    Article  CAS  PubMed  Google Scholar 

  34. Southey MC, Young MA, Whitty J, Mifsud S, Keilar M, Mead L, et al. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis. Am J Surg Pathol. 2001;25(7):936–41.

    Article  CAS  PubMed  Google Scholar 

  35. Mathiak M, Rutten A, Mangold E, Fischer HP, Ruzicka T, Friedl W, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol. 2002;26(3):338–43.

    Article  PubMed  Google Scholar 

  36. Cornejo KM, Hutchinson L, Deng A, Tomaszewicz K, Welch M, Lyle S, et al. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis. Hum Pathol. 2014;45(6):1213–20. doi:10.1016/j.humpath.2014.02.001.

    Article  CAS  PubMed  Google Scholar 

  37. Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL, Ivan D. American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012;119(5):1078–82. doi:10.1016/j.ophtha.2011.11.006.

    Article  PubMed  Google Scholar 

  38. Choi YJ, Jin HC, Lee MJ, Kim N, Choung HK, Khwarg SI. Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea. Jpn J Ophthalmol. 2014;58(4):327–33. doi:10.1007/s10384-014-0321-9.

    Article  PubMed  Google Scholar 

  39. Edge S, Editor. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  40. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, Gelfand JM, Whalen FM, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402–10. doi:10.1001/jamadermatol.2013.2456.

    Article  CAS  PubMed  Google Scholar 

  41. Hadravsky L, Kazakov DV, Stehlik J, Michal M, Curik R, Krupa P, et al. Aggressive extraocular sebaceous carcinoma of the scalp involving the brain in a patient with Muir-Torre syndrome. Am J Dermatopathol. 2016;38(8):618–22. doi:10.1097/dad.0000000000000524.

    Article  PubMed  Google Scholar 

  42. Herceg D, Kusacic-Kuna S, Dotlic S, Petrovic R, Bracic I, Horvatic Herceg G, et al. F-18 FDG PET evaluation of a rapidly growing extraocular sebaceous carcinoma. Clin Nucl Med. 2009;34(11):798–801. doi:10.1097/RLU.0b013e3181b7db6a.

    Article  PubMed  Google Scholar 

  43. Reina RS, Parry E. Aggressive extraocular sebaceous carcinoma in a 52-year-old man. Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2006;32(10):1283–6. doi:10.1111/j.1524-4725.2006.32292.x.

    CAS  Google Scholar 

  44. Orcurto A, Gay BE, Sozzi WJ, Gilliet M, Leyvraz S. Long-term remission of an aggressive sebaceous carcinoma following chemotherapy. Case Rep Dermatol. 2014;6(1):80–4. doi:10.1159/000360806.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017;76(2):217–25. doi:10.1016/j.jaad.2016.08.051.

    Article  PubMed  Google Scholar 

  46. Nijhawan N, Ross MI, Diba R, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg. 2004;20(4):291–5.

    Article  PubMed  Google Scholar 

  47. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103–22. doi:10.1016/j.survophthal.2004.12.008.

    Article  PubMed  Google Scholar 

  48. Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa. Arch Otolaryngol—Head Neck Surg. 2007;133(8):820–6. doi:10.1001/archotol.133.8.820.

    Article  PubMed  Google Scholar 

  49. Osada S, Ueno T, Inai S, Niimi Y, Nakamizo M, Ansai S, et al. Sebaceous carcinoma of the nose with a regional metastasis following false-negative sentinel lymph node biopsy. Acta Derm Venereol. 2011;91(3):367–8. doi:10.2340/00015555-1047.

    Article  PubMed  Google Scholar 

  50. Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection. JAMA Ophthalmol. 2013;131(8):1091–2. doi:10.1001/jamaophthalmol.2013.321.

    Article  PubMed  Google Scholar 

  51. • Thomas WW, Fritsch VA, Lentsch EJ. Population-based analysis of prognostic indicators in sebaceous carcinoma of the head and neck. Laryngoscope. 2013;123(9):2165–9. doi:10.1002/lary.24042. Tumor registry study reporting prognostic factors in head and neck sebaceous carcinoma based on 1433 cases in the SEER database

    Article  PubMed  Google Scholar 

  52. Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50. doi:10.1016/j.jaad.2012.06.009.

    Article  PubMed  Google Scholar 

  53. Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004–9. doi:10.1067/mjd.2001.113692.

    Article  CAS  PubMed  Google Scholar 

  54. Putterman AM. Conjunctival map biopsy to determine pagetoid spread. Am J Ophthalmol. 1986;102(1):87–90.

    Article  CAS  PubMed  Google Scholar 

  55. Tan KC, Lee ST, Cheah ST. Surgical treatment of sebaceous carcinoma of eyelids with clinico-pathological correlation. Br J Plast Surg. 1991;44(2):117–21.

    Article  CAS  PubMed  Google Scholar 

  56. Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg: Off Publ Am Soc Dermatol Surg [et al]. 2015;41(1):1–15. doi:10.1097/dss.0000000000000152.

    Article  CAS  Google Scholar 

  57. Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthal Plast Reconstr Surg. 2000;16(3):211–5.

    Article  CAS  PubMed  Google Scholar 

  58. Kumar V, Xu Y. Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours? Curr Oncol (Toronto, Ont). 2015;22(4):e316–9. doi:10.3747/co.22.2467.

    Article  CAS  Google Scholar 

  59. Della Vittoria Scarpati G, Perri F, Pisconti S, Costa G, Ricciardiello F, Del Prete S, et al. Concomitant cetuximab and radiation therapy: a possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. Mol Clin Oncol. 2016;4(4):467–71. doi:10.3892/mco.2016.746.

    PubMed  PubMed Central  Google Scholar 

  60. Ribero S, Baduel ES, Brizio M, Picciotto F, Dika E, Fierro MT, et al. Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. Radiol Oncol. 2016;50(3):308–12. doi:10.1515/raon-2016-0039.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Gogia A, Pushker N, Sen S, Bakhshi S. Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2013;251(10):2479–80. doi:10.1007/s00417-013-2382-8.

    Article  PubMed  Google Scholar 

  62. Kaliki S, Ayyar A, Nair AG, Mishra DK, Reddy VA, Naik MN. Neoadjuvant systemic chemotherapy in the management of extensive eyelid sebaceous gland carcinoma: a study of 10 cases. Ophthal Plast Reconstr Surg. 2016;32(1):35–9. doi:10.1097/iop.0000000000000398.

    Article  PubMed  Google Scholar 

  63. Poleksic S. Keratoacanthoma and multiple carcinomas. Br J Dermatol. 1974;91(4):461–3.

    Article  CAS  PubMed  Google Scholar 

  64. Finan MC, Connolly SM. Sebaceous gland tumors and systemic disease: a clinicopathologic analysis. Medicine. 1984;63(4):232–42.

    Article  CAS  PubMed  Google Scholar 

  65. Mangold E, Pagenstecher C, Leister M, Mathiak M, Rutten A, Friedl W, et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet. 2004;41(7):567–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Mangold E, Rahner N, Friedrichs N, Buettner R, Pagenstecher C, Aretz S, et al. MSH6 mutation in Muir-Torre syndrome: could this be a rare finding? Br J Dermatol. 2007;156(1):158–62. doi:10.1111/j.1365-2133.2006.07607.x.

    Article  CAS  PubMed  Google Scholar 

  67. • Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med: Off J Am Coll Med Genet. 2014;16(9):711–6. doi:10.1038/gim.2014.19. Study reporting on a novel clinical scoring system to identify patients with sebaceous neoplasms at risk for Muir Torre

    Article  Google Scholar 

  68. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science (New York, NY). 1993;260(5109):812–6.

    Article  CAS  Google Scholar 

  69. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558–61. doi:10.1038/363558a0.

    Article  CAS  PubMed  Google Scholar 

  70. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science (New York, NY). 1993;260(5109):816–9.

    Article  CAS  Google Scholar 

  71. Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol. 2001;116(2):246–53. doi:10.1046/j.1523-1747.2001.01233.x.

    Article  CAS  PubMed  Google Scholar 

  72. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. American Gastroenterological Association. Medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195–7.

    Article  Google Scholar 

  74. • Roberts ME, Riegert-Johnson DL, Thomas BC, Thomas CS, Heckman MG, Krishna M, et al. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns. 2013;22(3):393–405. doi:10.1007/s10897-012-9552-4. Retrospective review reporting on the utility of mismatch repair protein immunohistochemistry of sebaceous neoplasms for screening for Muir-Torre syndrome

    Article  PubMed  Google Scholar 

  75. Kacerovska D, Drlik L, Slezakova L, Michal M, Stehlik J, Sedivcova M, et al. Cutaneous sebaceous lesions in a patient with MUTYH-associated polyposis mimicking Muir-Torre syndrome. Am J Dermatopathol. 2016;38(12):915–23. doi:10.1097/dad.0000000000000649.

    Article  PubMed  Google Scholar 

  76. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976–85.e1-10. doi:10.1053/j.gastro.2009.08.052.

    Article  CAS  PubMed  Google Scholar 

  77. Ajith Kumar VK, Gold JA, Mallon E, Thomas S, Hodgson SV. Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin. Familial Cancer. 2008;7(2):187–9. doi:10.1007/s10689-007-9161-9.

    Article  PubMed  Google Scholar 

  78. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J cancer (Oxford, England : 1990). 2014;50(13):2241–50. doi:10.1016/j.ejca.2014.05.022.

    Article  CAS  Google Scholar 

  79. Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003;48(3):401–8. doi:10.1067/mjd.2003.97.

    Article  PubMed  Google Scholar 

  80. Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011;65(5):1054–8.e1. doi:10.1016/j.jaad.2010.08.003.

    Article  PubMed  Google Scholar 

  81. Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant Off J Am Soc Transplant Surg. 2007;7(2):476–9. doi:10.1111/j.1600-6143.2006.01648.x.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Mail Code A61, Cleveland, OH, 44195, USA

    Thomas Knackstedt MD

  2. Department of Dermatology, Columbia University Medical Center, New York, NY, 10032, USA

    Faramarz H. Samie MD, PhD

Authors
  1. Thomas Knackstedt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faramarz H. Samie MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Knackstedt MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Knackstedt, T., Samie, F.H. Sebaceous Carcinoma: A Review of the Scientific Literature. Curr. Treat. Options in Oncol. 18, 47 (2017). https://doi.org/10.1007/s11864-017-0490-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0490-0

Keywords

Search

Navigation